Last updated: 2026-10-14 20:43:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Vanda Pharmaceuticals Inc. (VNDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.22, with a market capitalisation of $274.50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.21 to $9.94. This page covers its latest market performance, valuation, price trends and company information.
$274.50M | |
$4.29 | |
$33.44 | |
$0.45 | |
$4.30 | |
706.88K | |
966.39K | |
-- | |
$9.94 | |
$4.21 | |
-- | |
-- |
Vanda Pharmaceuticals Inc. (VNDA) is trading at $4.22 in after-hours trading as of 2026-10-14 20:28:00, down 1.86% ($0.08) from the regular-session close of $4.30.
After-hours trading shows how investors are pricing VNDA after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Vanda Pharmaceuticals Inc. (VNDA) moved from $4.58 to $4.22, representing a decline of 7.97% ($0.37).
The stock traded between $4.21 and $4.64 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 883.78 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.2%
VNDA is currently trading at $4.22, placing it 0.2% of the way from its 52-week low of $4.21 to its 52-week high of $9.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 533 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vanda Pharmaceuticals Inc. (VNDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.